Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)
Celerion has vast experience with NAFLD/NASH investigation products, and understands the importance of detecting early signals of efficacy. With more than 10 years of metabolic research experience, our knowledgeable team of subject matter experts offers scientific and operational oversight across all lines of service.
As a leader in early clinical research, Celerion assists our clients with their “go/no-go” decisions. A breadth of pharmacodynamic services enables clients to examine the effect of NAFLD/NASH investigational products on hepatic lipid metabolism and fibrosis development. Celerion’s range of services includes:
- Fasting and postprandial lipid measurements
- Hepatic de novo lipogenesis by stable-label isotope tracer
- Lipid clearance assessments
- Indirect calorimetry
- Fingerstick ketones
- Ultrasound and MRI imaging
Celerion also has access to a number of soluble biomarkers of fibrosis and inflammation as well as lipidomic and metabolomic analyses.
With locations in the heart of culturally diverse cities, Celerion’s multi-centered sites offer effective recruiting strategies for healthy subjects and patients from disparate populations with a high prevalence of fatty liver disease. Moreover, we have established partnerships with a number of national health and community-based organizations to support our recruitment efforts.